Privium Fund Management B.V. Raises Position in Wave Life Sciences Ltd. (NASDAQ:WVE)

Privium Fund Management B.V. lifted its holdings in shares of Wave Life Sciences Ltd. (NASDAQ:WVE - Free Report) by 80.2% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 88,000 shares of the company's stock after buying an additional 39,166 shares during the period. Privium Fund Management B.V. owned approximately 0.06% of Wave Life Sciences worth $1,089,000 at the end of the most recent reporting period.

A number of other institutional investors also recently added to or reduced their stakes in WVE. KBC Group NV purchased a new position in shares of Wave Life Sciences in the fourth quarter worth approximately $67,000. Point72 DIFC Ltd purchased a new stake in shares of Wave Life Sciences in the third quarter valued at $98,000. Raymond James Financial Inc. acquired a new stake in shares of Wave Life Sciences in the fourth quarter worth $157,000. Victory Capital Management Inc. grew its holdings in shares of Wave Life Sciences by 16.6% during the fourth quarter. Victory Capital Management Inc. now owns 14,546 shares of the company's stock valued at $180,000 after buying an additional 2,073 shares in the last quarter. Finally, Orion Portfolio Solutions LLC acquired a new position in Wave Life Sciences during the third quarter valued at $123,000. Institutional investors and hedge funds own 89.73% of the company's stock.

Analyst Ratings Changes

WVE has been the topic of several research reports. Jefferies Financial Group began coverage on shares of Wave Life Sciences in a research note on Tuesday, February 25th. They issued a "buy" rating and a $26.00 price objective on the stock. StockNews.com upgraded Wave Life Sciences from a "sell" rating to a "hold" rating in a report on Saturday, March 8th. Finally, HC Wainwright reissued a "buy" rating and set a $22.00 price objective on shares of Wave Life Sciences in a research report on Wednesday, March 5th. Two analysts have rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $22.60.

Remove Ads

Wave Life Sciences Trading Down 0.8 %

NASDAQ WVE traded down $0.08 during trading on Friday, hitting $9.59. 1,619,845 shares of the company's stock were exchanged, compared to its average volume of 1,091,069. The company has a market cap of $1.47 billion, a PE ratio of -8.64 and a beta of -1.04. Wave Life Sciences Ltd. has a fifty-two week low of $4.25 and a fifty-two week high of $16.74. The stock's 50 day moving average price is $10.92 and its two-hundred day moving average price is $11.55.

Wave Life Sciences (NASDAQ:WVE - Get Free Report) last issued its quarterly earnings data on Tuesday, March 4th. The company reported $0.17 EPS for the quarter, beating the consensus estimate of ($0.17) by $0.34. The business had revenue of $83.75 million during the quarter, compared to the consensus estimate of $25.60 million. Wave Life Sciences had a negative net margin of 66.50% and a negative return on equity of 280.57%. Analysts forecast that Wave Life Sciences Ltd. will post -1.14 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Wave Life Sciences news, Director Christian O. Henry sold 10,500 shares of the company's stock in a transaction that occurred on Thursday, March 20th. The shares were sold at an average price of $9.77, for a total value of $102,585.00. Following the completion of the transaction, the director now directly owns 16,115 shares in the company, valued at approximately $157,443.55. This represents a 39.45 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Paul Bolno sold 169,025 shares of the firm's stock in a transaction on Friday, March 7th. The shares were sold at an average price of $9.57, for a total transaction of $1,617,569.25. Following the transaction, the chief executive officer now directly owns 338,351 shares of the company's stock, valued at $3,238,019.07. The trade was a 33.31 % decrease in their position. The disclosure for this sale can be found here. 29.10% of the stock is currently owned by corporate insiders.

Wave Life Sciences Profile

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.